At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
BGS649drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6 Month, Double-blind Safety Extension Study of MBGS205
In Brief
A Phase 2 clinical trial evaluating BGS649 for Hypogonadotropic Hypogonadism. Completed, enrolled 143 participants across 37 sites.
Detailed Summary
Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadotropic Hypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionSep 2018
Study CompletionNov 2018
TodayJul 2026
First PostedSep 20, 2016
Enrollment StartNov 15, 2016
Primary CompletionSep 8, 2018
Study CompletionNov 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.8 years ago
Interventions
BGS649drug
Capsules will be taken weekly for a maximum of 24 weeks